Drug Type Synthetic peptide |
Synonyms biomimetic peptide (Johns Hopkins University School of Medicine), AXT-120, AXT120 |
Target |
Action antagonists |
Mechanism VEGFR antagonists(Vascular endothelial growth factor receptor antagonists) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPreclinical |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Wet age-related macular degeneration | Preclinical | United States | 01 Jul 2018 | |
| Wet age-related macular degeneration | Preclinical | United States | 01 Jul 2018 | |
| Glaucoma, Neovascular | Preclinical | United States | - | |
| Glaucoma, Neovascular | Preclinical | United States | - |






